 "Granules India hits record high post USFDA inspection of Gagillapur facility")
Shares of Granules India has rallied 12% to Rs 1,017, also its record high on the BSE, after the pharmaceutical company said that US health regulator FDA (Food and Drug Administration) has inspected its Gagillapur manufacturing facility near Hyderabad and did not find any deviation from good manufacturing norms.
“US-FDA had inspected Gagillapur facility last week and the inspection concluded with no observations,” Granules India said in a BSE filing.
The inspection was triggered by one of the applicant’s Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.
The stock opened at Rs 950 and has seen more than two-fold jump in trading volumes. At 0953 hours, a combined 897,817 shares changed hands on the counter on NSE and BSE.
“US-FDA had inspected Gagillapur facility last week and the inspection concluded with no observations,” Granules India said in a BSE filing.
The inspection was triggered by one of the applicant’s Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.
The stock opened at Rs 950 and has seen more than two-fold jump in trading volumes. At 0953 hours, a combined 897,817 shares changed hands on the counter on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%